Lumira Ventures

Puzzle Medical Devices Inc., founded in 2018 and based in Montreal, Canada, focuses on developing innovative heart pump technologies for treating advanced heart failure. The company's flagship product, the ModulHeart, is a modular percutaneous heart pump designed to reduce cardiac afterload and enhance renal perfusion in patients who are not candidates for heart transplant or surgical mechanical circulatory support. Its unique design allows for multiple pumps to be anchored in parallel within the descending aorta, facilitating hemodynamic support while minimizing risks associated with traditional procedures, such as bleeding and stroke. The ModulHeart aims to improve patient outcomes by providing sustained symptom relief, reducing hospital readmissions, and enhancing overall quality of life. Puzzle Medical has made significant progress, including completing its first-in-human study with positive results in cardiac and kidney function, receiving FDA Breakthrough Device Designation, and establishing a strong network of Key Opinion Leaders in the field.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

Sound Blade Medical is an early-stage medical device company that specializes in developing innovative, non-invasive therapies using endoscopic histotripsy. This technology employs focused ultrasound, guided by real-time imaging, to precisely destroy targeted tissue without heat, ionizing radiation, or surgical invasion. The company aims to revolutionize healthcare by enhancing endoscopic procedures, offering a more precise and safer alternative to traditional treatments.

Spectrawave, Inc. is a medical device company based in Waltham, Massachusetts, founded in 2017. The company specializes in developing and manufacturing optical diagnostic and therapeutic devices aimed at enhancing the diagnosis and treatment of cardiovascular diseases. One of its key innovations is a spectroscopy catheter that integrates advanced imaging technologies to improve outcomes for patients with coronary artery disease (CAD). This cutting-edge imaging system provides interventional cardiologists with crucial optical and computational insights, enabling them to identify patients and plaque formations that may pose risks for future coronary complications. Through its focus on photonics, Spectrawave aims to optimize stent interventions and improve overall patient care in the field of cardiovascular medicine.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Endogenex is a medical technology company founded in 2017 that focuses on developing an innovative endoscopic procedure to assist patients with type 2 diabetes in managing their blood glucose levels. The company has created a unique therapy that employs pulsed electric fields to promote the regeneration of the duodenal mucosa, which contributes to enhanced glycemic control. By providing this novel treatment option, Endogenex aims to improve the quality of life for individuals living with type 2 diabetes.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that features a proprietary dry-powder formulation of dihydroergotamine mesylate. This product is designed for self-administration through a pre-filled, single-use nasal delivery device and is currently undergoing Phase III clinical trials. Founded in 2016 and based in South San Francisco, California, Satsuma aims to provide an effective therapeutic option for individuals suffering from acute migraine episodes.

Bardy Diagnostics, Inc. is a medical device company that specializes in the development and manufacturing of cardiac monitoring solutions, primarily focused on arrhythmia detection. Its flagship product, the Carnation Ambulatory Monitor (CAM), is a lightweight, discreet cardiac patch that can be worn comfortably for up to seven days, even during physical activities like exercise or showering. The CAM is designed with a unique hourglass shape to enhance comfort, particularly for female patients. Complementing the monitor is the BDxCONNECT patient management system, which allows healthcare providers to create and manage patient reports efficiently. By utilizing innovative P-wave centric ECG detection technology, Bardy Diagnostics aims to improve clinical management and outcomes for patients and their physicians. Founded in 2013, the company is headquartered in Seattle, Washington, with additional offices in Houston, Texas, and New Providence, New Jersey.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Exact Imaging specializes in high-resolution micro-ultrasound systems aimed at improving real-time imaging and guided biopsies in the urological sector, particularly for prostate cancer. The company's flagship product, the ExactVu system, operates at 29 MHz, providing exceptional resolution that allows for the visualization and targeting of suspicious regions. In addition to enabling precise systematic biopsies, Exact Imaging offers the FusionVu application, which integrates micro-ultrasound with MRI to enhance prostate imaging and biopsy accuracy. Founded in 2003 and headquartered in Markham, Canada, the company was previously known as Imagistx, Inc. before rebranding in 2015.

Endotronix Inc. is a developer of advanced hemodynamic monitoring technologies focused on early detection of worsening heart failure. Founded in 2007 and based in Lisle, Illinois, the company specializes in miniaturized, wireless, and implantable pressure sensors that are utilized in interventional cardiovascular procedures. These sensors connect to an external measurement device and are part of a comprehensive platform that includes cloud-based disease management and outpatient hemodynamic management. Endotronix's innovative tools facilitate patient management by linking patients, clinicians, and reimbursement teams, ultimately enhancing clinical and economic outcomes. The company's technology aims to improve proactive heart management and empower health professionals to monitor patients' conditions effectively from home.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

Exact Imaging specializes in high-resolution micro-ultrasound systems aimed at improving real-time imaging and guided biopsies in the urological sector, particularly for prostate cancer. The company's flagship product, the ExactVu system, operates at 29 MHz, providing exceptional resolution that allows for the visualization and targeting of suspicious regions. In addition to enabling precise systematic biopsies, Exact Imaging offers the FusionVu application, which integrates micro-ultrasound with MRI to enhance prostate imaging and biopsy accuracy. Founded in 2003 and headquartered in Markham, Canada, the company was previously known as Imagistx, Inc. before rebranding in 2015.

Exact Imaging specializes in high-resolution micro-ultrasound systems aimed at improving real-time imaging and guided biopsies in the urological sector, particularly for prostate cancer. The company's flagship product, the ExactVu system, operates at 29 MHz, providing exceptional resolution that allows for the visualization and targeting of suspicious regions. In addition to enabling precise systematic biopsies, Exact Imaging offers the FusionVu application, which integrates micro-ultrasound with MRI to enhance prostate imaging and biopsy accuracy. Founded in 2003 and headquartered in Markham, Canada, the company was previously known as Imagistx, Inc. before rebranding in 2015.

Engage Therapeutics, based in Summit, New Jersey, is a biopharmaceutical company focused on developing innovative therapies for individuals experiencing uncontrolled epileptic seizures. The company's lead product, Staccato® alprazolam, is a handheld drug-device combination that utilizes an established FDA-approved delivery system to administer alprazolam, an FDA-approved benzodiazepine. This product aims to provide immediate rescue therapy for active seizures, offering a potential solution for patients and their caregivers. In a Phase 2a proof of concept study, Staccato alprazolam demonstrated efficacy in reducing seizures in a photosensitivity model. Engage Therapeutics plans to advance this product into further clinical development through a 505(b)(2) regulatory pathway, positioning it as a promising option for seizure management.

Exact Imaging specializes in high-resolution micro-ultrasound systems aimed at improving real-time imaging and guided biopsies in the urological sector, particularly for prostate cancer. The company's flagship product, the ExactVu system, operates at 29 MHz, providing exceptional resolution that allows for the visualization and targeting of suspicious regions. In addition to enabling precise systematic biopsies, Exact Imaging offers the FusionVu application, which integrates micro-ultrasound with MRI to enhance prostate imaging and biopsy accuracy. Founded in 2003 and headquartered in Markham, Canada, the company was previously known as Imagistx, Inc. before rebranding in 2015.

Endotronix Inc. is a developer of advanced hemodynamic monitoring technologies focused on early detection of worsening heart failure. Founded in 2007 and based in Lisle, Illinois, the company specializes in miniaturized, wireless, and implantable pressure sensors that are utilized in interventional cardiovascular procedures. These sensors connect to an external measurement device and are part of a comprehensive platform that includes cloud-based disease management and outpatient hemodynamic management. Endotronix's innovative tools facilitate patient management by linking patients, clinicians, and reimbursement teams, ultimately enhancing clinical and economic outcomes. The company's technology aims to improve proactive heart management and empower health professionals to monitor patients' conditions effectively from home.

BAROnova, Inc. is a clinical-stage medical-device company established in 2006 and based in Goleta, California. The company specializes in creating non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a straightforward endoscopic procedure. This device works by helping patients feel fuller more quickly, maintain that feeling of fullness for a longer duration, and delay gastric emptying. Through these innovative approaches, BAROnova aims to assist individuals in managing their weight effectively.

BAROnova, Inc. is a clinical-stage medical-device company established in 2006 and based in Goleta, California. The company specializes in creating non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a straightforward endoscopic procedure. This device works by helping patients feel fuller more quickly, maintain that feeling of fullness for a longer duration, and delay gastric emptying. Through these innovative approaches, BAROnova aims to assist individuals in managing their weight effectively.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

Corvia Medical, Inc., established in 2009 and based in Andover, Massachusetts, is a medical device company specializing in structural heart devices for heart failure treatment. Its primary product is the InterAtrial Shunt Device (IASD), a transcatheter device designed to alleviate symptoms and slow the progression of diastolic heart failure, also known as heart failure with preserved ejection fraction (HFpEF). The IASD system reduces elevated left atrial pressure, the primary cause of DHF symptoms, by creating a small opening between the left and right atria, enabling patients to lead healthier lives with reduced heart failure risk.

Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, dedicated to developing non-fusion motion preservation systems for treating degenerative diseases of the spine. Founded in 2003, the company offers two primary products: the M6-C artificial cervical disc and the M6-L artificial lumbar disc, both designed to replicate the anatomical and biomechanical characteristics of natural intervertebral discs. These innovations provide options for artificial disc replacement in the cervical and lumbar regions. Spinal Kinetics collaborates with spine surgeons to ensure that its products meet clinical needs and are sold through a network of distributors across various countries, including Australia, Germany, the United Kingdom, and the United Arab Emirates. The company operates as a subsidiary of Orthofix Medical Inc.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

Corvia Medical, Inc., established in 2009 and based in Andover, Massachusetts, is a medical device company specializing in structural heart devices for heart failure treatment. Its primary product is the InterAtrial Shunt Device (IASD), a transcatheter device designed to alleviate symptoms and slow the progression of diastolic heart failure, also known as heart failure with preserved ejection fraction (HFpEF). The IASD system reduces elevated left atrial pressure, the primary cause of DHF symptoms, by creating a small opening between the left and right atria, enabling patients to lead healthier lives with reduced heart failure risk.

BAROnova, Inc. is a clinical-stage medical-device company established in 2006 and based in Goleta, California. The company specializes in creating non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a straightforward endoscopic procedure. This device works by helping patients feel fuller more quickly, maintain that feeling of fullness for a longer duration, and delay gastric emptying. Through these innovative approaches, BAROnova aims to assist individuals in managing their weight effectively.

Usystems specializes in the design, development, and manufacture of advanced ultrasound systems and software aimed at enhancing breast cancer detection, particularly in women with dense breast tissue. The company's innovative products provide high-quality 3D ultrasound images that assist radiologists in identifying areas of concern within breast tissue. In addition to its focus on medical imaging, Usystems is dedicated to creating cutting-edge racking enclosures and cooling solutions that minimize noise, heat, and operational costs in data centers and office environments. Through a commitment to quality and innovation, Usystems employs state-of-the-art manufacturing processes to deliver effective solutions in both healthcare and data management sectors.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.